Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.

Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.

For non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Optimised protoc...

Full description

Bibliographic Details
Main Authors: Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5552229?pdf=render

Internet

http://europepmc.org/articles/PMC5552229?pdf=render

Similar Items